

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	Tildrakizumab
Brand Name	Illumya™
Dosage Form	100 mg/mL single-dose pre-filled syringe for subcutaneous (SC) injection
Manufacturer	Sun Pharma Canada Inc.
Submission Type	New Submission
Use Reviewed	For the treatment of adult patients with moderate-to-severe plaque psoriasis.
Common Drug Review (CDR)	Yes, CDR recommended: to Reimburse with clinical criteria and/or conditions . Visit the CDR website for more details: https://cadth.ca/sites/default/files/cdr/complete/SR0624%20Illumya%20-%20CDEC%20Final%20Recommendation%20June%2023%2C%202021_for%20posting%20(1).pdf
Provincial Review	The Drug Benefit Council (DBC) screens drug submissions under review by the CDR to determine whether a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry of Health's (the Ministry's) drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. The DBC screened tildrakizumab in September 2019. The DBC advised that, because tildrakizumab is similar to other drugs used for the treatment of plaque psoriasis, the Ministry may accept the CDEC's recommendation for tildrakizumab.
Drug Coverage Decision	Non-Benefit
Date	February 22, 2022

Reasons	<p>Drug coverage decision is consistent with the CDEC recommendation.</p> <ul style="list-style-type: none"> • The drug did not demonstrate advantages over other biologic treatments currently reimbursed for the treatment of moderate-to-severe plaque psoriasis with respect to efficacy, safety, and quality of life. • Based on economic considerations and the submitted product price, the drug was not cost effective and did not offer optimal value for money. • The Ministry did not participate in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer because the drug did not demonstrate clinical or economic advantages as compared to existing treatments reimbursed by PharmaCare for plaque psoriasis, including other drug therapies with a similar mechanism of action as tildrakizumab. • There is no comparative evidence of superiority of tildrakizumab compared to other biologic treatments for plaque psoriasis to warrant a price premium for the drug.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.